arrow
N

Nathaniel M. Lewis

Centers for Disease Control and Prevention
H指数:37
被引数:4,060

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Influenza vaccine effectiveness against influenza A-associated hospitalization and severe in-hospital outcomes among adults in the United States, 2024–2025

2024–2025年度美国成人人群中流感疫苗对流感A相关住院及院内严重结局的保护效果

2026-09-260
PRE
Differences in influenza vaccine effectiveness by sex among adults hospitalized with acute respiratory illness—IVY network, January 24, 2022–September 1, 2024
Vaccine
IF3.5
2026-01-090
PRE
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States-2017-2020

临床表现的严重程度及住院成人流感患者的结局:按类型和亚型分类,美国-2017-2020

2025-10-010
PRE
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus

成人呼吸道合胞病毒感染的多重共病模式与院内严重预后

2025-08-010
PRE
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024

疫苗对流感A(H1N1)、A(H3N2)和B相关住院的效力,美国,2023年9月1日至2024年5月31日

2025-04-080
PRE
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination

与呼吸道合胞病毒疫苗接种相关的患者层面和社区层面特征

2025-04-010
OA
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study

早期奥司他韦治疗对甲型流感住院成人患者的益处: 一项观察性研究

2024-11-281
OA
Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023

2022年9月-2023年8月,原始单价和二价新型冠状病毒肺炎疫苗对美国成人COVID-19-Associated住院和严重住院结局的有效性

2024-11-040
OA
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024

更新的2023-2024 (单价XBB.1.5) 新型冠状病毒肺炎接种SARS-CoV-2 Omicron XBB和BA.2.86/JN.1的有效性谱系住院和临床严重程度的比较-IVY Network,26家医院,2023年10月18日-2024 3月9日

2024-08-069
OA
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023

疫苗对甲型流感相关住院,器官衰竭和死亡的有效性: 美国,2022-2023

2023-12-0519
OA
Risk for Infection in Humans after Exposure to Birds Infected with Highly Pathogenic Avian Influenza A(H5N1) Virus, United States, 2022
2023-06-0114
OAAI
Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons-29 US Jurisdictions, May 22-September 3, 2022
2023-02-015
PRE
Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022
2022-12-3111
OAAI
One Health Investigation of SARS-CoV-2 in People and Animals on Multiple Mink Farms in Utah
2022-12-296
OAAI
Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022
2022-11-0315
OA
Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness
2022-07-1119
OA